The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.20
Change: -0.90 (-29.51%)
Spread: 0.10 (4.762%)
Open: 2.70
High: 2.70
Low: 2.05
Prev. Close: 3.05
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shareholder Communications

17 Aug 2022 07:00

RNS Number : 2408W
ValiRx PLC
17 August 2022
 

17 August 2022

 

ValiRx PLC ("ValiRx" or the "Company")

 

Shareholder Communications

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce the appointment of strategic marketing and PR agency, V Formation Limited and the appointment of Dr Adam Hargreaves as a shareholder representative. The appointments represent the Company's continued strategy to improve and enhance communications with its shareholders.

V Formation Limited is a Nottingham-based public relations and marketing communications agency that specialises in supporting clients in the life sciences sector, ensuring that news and corporate development updates are optimised and communicated in a clear, transparent and precise manner. V Formation will liaise closely with Dr Hargreaves in his role as shareholder representative, as well as with ValiRx's Nominated Adviser and brokers, to improve the interpretation and dissemination of Company newsflow following publication via a regulatory information provider.

Dr Adam Hargreaves has agreed to become a shareholder representative to help improve communications between the Company and shareholders. The Company's overall policy on shareholder communications is unchanged, with written quarterly updates and quarterly live Q&A events continuing. However, shareholders can additionally communicate with Dr Hargreaves directly to seek clarification of any details that have been publicly announced, or through a shareholder community. Dr Hargreaves will have regular interaction with the Company to ensure that shareholders' views are fully represented to the Board. Shareholders wishing to communicate directly with Board members are welcome to do so, with a prompt response when possible.

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

 

Dr Suzanne Dilly, CEO

 

Dr Adam Hargreaves, Shareholder Representative

 

Tel: +44 (0) 2476 796496

www.valirx.com

Suzanne.Dilly@valirx.com

 

Adam.Hargreaves@pathcelerate.com

V Formation (Public Relations)

 

Lucy Wharton - Senior PR Executive

Sue Carr - Director

 

 

Contact details

www.vformation.biz

lucy@vformation.biz

sue@vformation.biz

+44 (0)115 787 0206

Cairn Financial Advisers LLP (Nominated Adviser)

 

Liam Murray/Jo Turner/Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 088

Cenkos Securities Limited (Joint Broker)

 

Russell Kerr/Michael Johnson (Sales)

 

Callum Davidson/Giles Balleny (Corporate Finance)

Tel: +44 (0) 20 7397 8900

Turner Pope Investments (Joint Broker)

James Pope / Andy Thacker  

Tel: +44 (0) 20 3657 0050

 

 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

About V Formation

V Formation is an established marketing and PR agency based at BioCity Nottingham. The team of experienced marketing and PR consultants deliver inspiring, insightful and supportive marketing advice, strategy and tactics to take businesses closer to their clients and help them find their competitive edge. 

 

V Formation works with ambitious SMEs in the life sciences and high-tech sectors, professional services firms and family businesses. It provides in-house marketing and support, guidance on strategic direction and assistance with tactical marketing and PR. The company's directors are Sue Carr and Hilary Campton.

 

For more information: www.vformation.biz or 0115 822 6364 

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDIISBDGDL
Date   Source Headline
28th Jul 20167:00 amRNSNotification of New Zealand Patent Grant Allowance
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant
24th Feb 20157:00 amRNSSuccessful 1st Results from VAL201 Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.